How is it considered or taken into account?

January 20, 2020 Latest News

This is a preview of subscriber content

Subscribe now to continue reading.

The MOGA PBAC submission can be reproduced because it is simple and based on publicly available information. The submission contains nothing unique to MOGA or anything reflecting the extensive training and expertise of medical oncologists. …

Subscribe now to continue reading.

Latest Video

UK industry cites US pricing ambitions in collapse of new agreement negotiation
August 25, 2025 - Latest News
Mark Butler asking questions about Trump's 'Most Favored Nation' pricing push
August 27, 2025 - Latest News
PBAC delivers recommendations dominated by price cuts and risk shares
August 25, 2025 - Latest News
The next negotiation was always going to be complicated, the new reality will make it more so
August 25, 2025 - Latest News
'Patients can’t wait – swift action and access are the only possible moves from here'
August 26, 2025 - Latest News

How is it considered or taken into account?

This is a preview of subscriber content

Latest Video

Most Read

UK industry cites US pricing ambitions in collapse of new agreement negotiation

Mark Butler asking questions about Trump's 'Most Favored Nation' pricing push

PBAC delivers recommendations dominated by price cuts and risk shares

The next negotiation was always going to be complicated, the new reality will make it more so

'Patients can’t wait – swift action and access are the only possible moves from here'

New Stories

Cartherics secures Chinese patent to boost immune cell function in solid tumours

NeuroScientific’s StemSmart MSC therapy shows promise in kidney transplantation

Starpharma advances dendrimer platform with clinical, commercial, and strategic progress

Biome achieves breakthrough year with first profit and rapid global expansion

Neuren doubles profit as DAYBUE royalties and pipeline progress drive growth

Sigma Healthcare delivers strong first-year results after Chemist Warehouse merger

Mark Butler asking questions about Trump's 'Most Favored Nation' pricing push

Sign In

How is it considered or taken into account?

This is a preview of subscriber content

Latest Video

Most Read

UK industry cites US pricing ambitions in collapse of new agreement negotiation

Mark Butler asking questions about Trump's 'Most Favored Nation' pricing push

PBAC delivers recommendations dominated by price cuts and risk shares

The next negotiation was always going to be complicated, the new reality will make it more so

'Patients can’t wait – swift action and access are the only possible moves from here'

Follow Us

New Stories

Cartherics secures Chinese patent to boost immune cell function in solid tumours

NeuroScientific’s StemSmart MSC therapy shows promise in kidney transplantation

Starpharma advances dendrimer platform with clinical, commercial, and strategic progress

Biome achieves breakthrough year with first profit and rapid global expansion

Neuren doubles profit as DAYBUE royalties and pipeline progress drive growth

Sigma Healthcare delivers strong first-year results after Chemist Warehouse merger

Mark Butler asking questions about Trump's 'Most Favored Nation' pricing push